Introduction: Neonatal brain development is vulnerable to anesthetic-induced neurotoxicity from multiple exposures, especially during complex cardiac surgery. While brief exposures to anesthetics in healthy children are safe, the risks of systemic inflammation and instability in neonates remain a concern. Dexmedetomidine (DEX), an alpha-2 agonist, offers potential neuroprotection without the GABA-mediated toxicity seen in other agents. This review evaluates DEX's efficacy in mitigating neurotoxicity and improving outcomes in high-risk neonates.
Objective: To investigate the impact of perioperative dexmedetomidine on molecular markers of neurotoxicity, perioperative clinical outcomes, and long-term neurodevelopment in neonates undergoing congenital cardiac surgery. Methods: PubMed, Google Scholar, ClinicalKey, and OpenEvidence were searched. Keywords included Dexmedetomidine, Neonatal Neurotoxicity, and Congenital Heart Surgery. Inclusion criteria focused on human clinical trials (neonates to infants <1 year) and supporting preclinical neonatal models. Analysis included data from randomized controlled trials (RCTs), meta-analyses, and preclinical studies focusing on cellular apoptosis and cognitive metrics
Results: Mechanistically, DEX exerts neuroprotection by stabilizing mitochondria and preserving membrane potential, thereby reducing isoflurane-associated caspase-3 activation. Clinically, DEX administration suppressed pro-inflammatory cytokines (IL-6) and brain injury markers (NSE) during CPB. While DEX improved perioperative stability, enhanced pain management, and reduced emergence delirium, long-term neurodevelopmental assessments spanning from neonates through age 3 (e.g., Bayley Scales at 1–2 years) remain inconclusive. Large RCTs showed no significant long-term neurodevelopmental difference compared to standard regimens.
Conclusion: DEX provides promising anti-inflammatory and anti-apoptotic benefits during neonatal cardiac surgery. Although clinicians must monitor for bradycardia and hypotension, DEX improves perioperative stability. However, further longitudinal research is necessary to determine if these molecular advantages translate into superior long-term neurodevelopmental outcomes.
Objective: To investigate the impact of perioperative dexmedetomidine on molecular markers of neurotoxicity, perioperative clinical outcomes, and long-term neurodevelopment in neonates undergoing congenital cardiac surgery. Methods: PubMed, Google Scholar, ClinicalKey, and OpenEvidence were searched. Keywords included Dexmedetomidine, Neonatal Neurotoxicity, and Congenital Heart Surgery. Inclusion criteria focused on human clinical trials (neonates to infants <1 year) and supporting preclinical neonatal models. Analysis included data from randomized controlled trials (RCTs), meta-analyses, and preclinical studies focusing on cellular apoptosis and cognitive metrics
Results: Mechanistically, DEX exerts neuroprotection by stabilizing mitochondria and preserving membrane potential, thereby reducing isoflurane-associated caspase-3 activation. Clinically, DEX administration suppressed pro-inflammatory cytokines (IL-6) and brain injury markers (NSE) during CPB. While DEX improved perioperative stability, enhanced pain management, and reduced emergence delirium, long-term neurodevelopmental assessments spanning from neonates through age 3 (e.g., Bayley Scales at 1–2 years) remain inconclusive. Large RCTs showed no significant long-term neurodevelopmental difference compared to standard regimens.
Conclusion: DEX provides promising anti-inflammatory and anti-apoptotic benefits during neonatal cardiac surgery. Although clinicians must monitor for bradycardia and hypotension, DEX improves perioperative stability. However, further longitudinal research is necessary to determine if these molecular advantages translate into superior long-term neurodevelopmental outcomes.